Peer-reviewed veterinary case report
How benzoporphyrin derivative works in dogs with tumors
By Osaki, T et al.·Published in Journal of veterinary medicine. A, Physiology, pathology, clinical medicine·2006·Department of Veterinary Clinical Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical pharmacokinetics of anti-angiogenic photodynamic therapy with benzoporphyrin derivative monoacid ring-A in dogs having naturally occurring neoplasms.
- Species:
- dog
Plain-English summary
A group of nine dogs with naturally occurring tumors received an injection of a photosensitizer called benzoporphyrin derivative monoacid ring-A (BPD-MA) as part of a treatment called photodynamic therapy (PDT). After the injection, the medication stayed in the dogs' systems for an average of over eight hours, and no significant side effects were noted except for a slight increase in a liver enzyme. This study suggests that understanding how BPD-MA behaves in dogs can help veterinarians create better treatment plans for using PDT to target tumors.
People also search for: dog cancer treatment · photodynamic therapy for dogs · benzoporphyrin derivative for tumors in dogs
Abstract
The aim of this study was to examine the pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; Verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms. After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life (t1/2) was found to be 8.14 +/- 5.34 h, mean clearance (Cl) 35.13 +/- 9.62 ml/(h kg), the mean value of the volume of distribution (Vc) 0.08 +/- 0.01 l/kg and the mean steady state volume of distribution (Vss) 0.38 +/- 0.31 l/kg respectively. With the exception of a transitional increase in serum alkaline phosphatase activity, no other clinical abnormalities were observed. The t1/2 in dogs with naturally occurring tumours was longer than that in humans, but similar to that in rats. The values of Cl and Vss in dogs having naturally occurring neoplasms were lower than those in humans. It is suggested that the pharmacokinetics of BPD-MA in tumour-bearing dogs would be helpful in determining the protocol of a short drug-light interval PDT with BPD-MA that mainly targets the tumour vasculature.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16466464/